Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Cognivia is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Dominique Demolle appears in 1 tracked Biotech story from July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Cognivia is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. Dominique Demolle appears in 1 tracked Biotech story from July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dominique Demolle. Shared-story counts are live from our verified record — not editorial picks.
Cognivia and Mayo Clinic are zeroing in on non-adherence, missed appointments, and trial dropout—three behavioral factors that inflate clinical trial costs and delay drug development. By making patient behavior measurable, the partnership could help biopharma sponsors de-risk studies and improve real-world evidence.
Source: prnewswire.com · prnewswire.com
Dominique Demolle is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
